Roche-backed Chugai taps into longevity field with Pfizer-allied Gero

Kyle LaHucik

Biotech Correspondent

Japanese drugmaker Chugai is wading into the aging-related disease landscape, an area of drug R&D that’s gaining more traction among pharmaceutical giants.

The Tokyo-headquartered company …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Roche-backed Chugai taps into longevity field with Pfizer-allied Gero

Kyle LaHucik

Biotech Correspondent

Sign up to read this article for free.

Apogee reports Phase 2 win for eczema drug that could challenge Dupixent and Ebglyss

Despite delay, KalVista wins FDA approval after Makary's short-lived attempt to intervene

Compromised drug lot impacts Jasper's chronic hives study, stock falls

Cogent’s mastocytosis drug hits ‘home run’ in registrational mid-stage trial

Novartis' Cosentyx fails Phase 3 study for autoimmune disease

Uncovering the Potential of Targeting the CD38 Pathway for Immune-Mediated Diseases

Roche-backed Chugai taps in­to longevi­ty field with Pfiz­er-al­lied Gero

Kyle LaHucik

Biotech Correspondent

Sign up to read this article for free.

Apogee re­ports Phase 2 win for eczema drug that could chal­lenge Dupix­ent and Ebglyss

De­spite de­lay, KalVista wins FDA ap­proval af­ter Makary's short-lived at­tempt to in­ter­vene

Com­pro­mised drug lot im­pacts Jasper's chron­ic hives study, stock falls

Co­gent’s mas­to­cy­to­sis drug hits ‘home run’ in reg­is­tra­tional mid-stage tri­al

No­var­tis' Cosen­tyx fails Phase 3 study for au­toim­mune dis­ease

Un­cov­er­ing the Po­ten­tial of Tar­get­ing the CD38 Path­way for Im­mune-Me­di­at­ed Dis­eases

Roche-backed Chugai taps into longevity field with Pfizer-allied Gero

Apogee reports Phase 2 win for eczema drug that could challenge Dupixent and Ebglyss

Despite delay, KalVista wins FDA approval after Makary's short-lived attempt to intervene

Compromised drug lot impacts Jasper's chronic hives study, stock falls

Cogent’s mastocytosis drug hits ‘home run’ in registrational mid-stage trial

Novartis' Cosentyx fails Phase 3 study for autoimmune disease

Uncovering the Potential of Targeting the CD38 Pathway for Immune-Mediated Diseases